Senior Data Scientist, RWE at Tempus

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Precision Medicine, Pharmaceuticals, OncologyIndustries

Requirements

Masters or PhD Degree in epidemiology, biostatistics, health economics or a related discipline and 5+ years of post-grad experience
Experience in conducting observational retrospective analyses in oncology including a published track record
Computational skills using R and SQL, especially relevant statistical tools and packages
Ideal Requirements
Prior involvement in oncology Phase II-IV clinical trials or proven expertise in analyzing RWD studies, including utilization of claims, EHR, or registry data
Demonstrated experience interfacing with clients or in a consulting capacity, showcasing adeptness in presenting results to stakeholders
Proficiency in navigating large, complex problems within a fast-paced environment
Meticulous attention to detail coupled with a commitment to delivering analytics of the highest quality and punctuality
A collaborative mindset, coupled with a genuine eagerness to learn and a steadfast dedication to maintaining integrity in all endeavors
Direct involvement in assisting with the preparation of regulatory submissions to the FDA or EMA
Proficiency in machine learning techniques, with a nuanced understanding of the strengths and limitations of various approaches, particularly regarding predictive and prognostic algorithms in medical research
Familiarity with cancer genetics, immunology, or molecular biology

Responsibilities

Contribute to the design and execution of RWE studies by developing protocols, crafting statistical analysis plans, and creating analysis deliverables such as table shells, leveraging Tempus’s data to support external Pharma Medical Affairs, HEOR, and RWE team objectives
Lead independent analysis of Tempus data for Pharma RWE studies, involving extensive coding, comprehension of Tempus molecular and clinical data, acquisition of oncology-specific clinical insights, derivation of real-world endpoints using time-to-event methodology, and staying abreast of current NCCN guidelines and the evolving oncology landscape within a retrospective database
Present insights from RWE studies to external Pharma epidemiologists and medical liaisons through formal presentations, providing strategic recommendations
Communicate research findings effectively, interpreting results and drawing appropriate inferences based on study design/statistical methods, while also evaluating study limitations
Collaborate with internal product, engineering, oncology, bioinformatics, and clinical abstraction teams to continually enhance Tempus data quality and feature builds for retrospective analysis
Work with translational research and computational biologists to analyze Tempus sequencing data within RWE studies
Stay updated on methodological advancements in real-world studies, oncology guidelines, and ongoing clinical trials
Demonstrate proficiency in various types of RWD and their suitability for analysis, distinguishing between retrospective RWD, clinical trials, and other prospective observational study designs, and articulating their advantages and limitations
Ensure compliance with all relevant regulations and company procedures

Skills

Epidemiology

Pharmacoepidemiology

RWE

Statistical Analysis

Protocol Development

Statistical Programming

Time-to-Event Analysis

Oncology

NCCN Guidelines

Real-World Data

HEOR

Tempus

AI-driven healthcare data analysis platform

About Tempus

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.

Chicago, IllinoisHeadquarters

2015Year Founded

$894.9MTotal Funding

IPOCompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Risks

Competition from partners like Genialis may lead to conflicts of interest.

Ambry Genetics acquisition could pose financial risks if synergies aren't realized.

Technical challenges may arise in integration with Flatiron's OncoEMR platform.

Differentiation

Tempus uses AI to analyze clinical and molecular data for precision medicine.

Their platform aids in personalized treatment decisions for cancer patients.

Tempus collaborates with biotech firms to enhance drug development using real-world data.

Upsides

Increased AI adoption in healthcare boosts Tempus' partnerships and collaborations.

Acquisition of Ambry Genetics expands Tempus' genetic testing capabilities.

Integration with Flatiron's OncoEMR enhances precision in cancer treatment plans.

Land your dream remote job 3x faster with AI

Try Jobo Free